GHK-Cu 100mg Dosage Protocol

Cycle

Suggested schedule (anecdotal): 8–12 weeks on a megadose ramp (standard cycle below), then ongoing medium dose (2.5 mg/day) or a 4-week off phase.

Standard Cycle

Duration	Dose per injection	U-100 units	Volume
Weeks 1–4	1.5 mg	4.5 units	0.045 mL
Weeks 5–8	3 mg	9 units	0.09 mL
Weeks 9–12	5 mg	15 units	0.15 mL
Week 12+ (maintenance)	2.5 mg	7.5 units	0.075 mL

Daily subcutaneous injectable and/or 1–2× daily topical.

At 5 mg/day injectable, one 100 mg vial lasts about 20 days. Fewer vials to reconstitute over a full cycle than the 50 mg format.

Supplies

Supplies for Standard Cycle

Counts below cover a full 12-week standard cycle with daily subQ injection (84 injection days). Assumes 1 fresh needle per injection and 2 alcohol swabs per injection (vial + skin).

Also needed: 1 sharps container, refrigerator space for reconstituted vials, and labels for mix date. Round syringe and swab counts up if you prefer a buffer.

General supplies

• GHK-Cu 100 mg lyophilised vial(s)
• Bacteriostatic water (BAC), 10 mL or 30 mL vial
• U-100 insulin syringes, 1 mL, 29G–31G × ½″
• Alcohol swabs
• Sharps container
• Refrigerator space for reconstituted vial
• Optional (topical): plain fragrance-free moisturiser, serum, or soap base
• Optional (topical): microneedling pen if using that protocol

Dosing & Reconstitution

Reconstitution

Recommended BAC water: 3 mL → 100 mg ÷ 3 mL = 33.33 mg/mL. Standard research vials hold ~3 mL liquid max; do not overfill.

1. Swab the rubber stoppers on the GHK-Cu vial and BAC vial. Let dry.
2. Draw 3 mL bacteriostatic water (1 mL at a time if using a 1 mL syringe).
3. Inject slowly down the inside wall of the peptide vial. Do not shoot directly onto the powder.
4. Swirl gently until clear. Do not shake.
5. Label with date and BAC volume. Refrigerate immediately.

With BAC, expect roughly 25–30 days stability refrigerated. See the Storage Guide.

Topical cosmetic trials often run 12 weeks before results are assessed, which aligns with common community cycles for skin-focused goals. Shorter runs may still show early changes; longer continuous use without breaks has less formal data for injectable routes.

Injectable dosing

Subcutaneous injection is the common research route for systemic and skin-from-within effects.

Level	Daily dose	Volume (33.33 mg/mL)	U-100 units	Days per vial
Low	2.5 mg	0.075 mL	7.5 units	40
Medium	5 mg	0.15 mL	15 units	20
High	7.5 mg	0.225 mL	22.5 units	13–14
High	10 mg	0.30 mL	30 units	10

Formula: dose volume = desired mg ÷ 33.33. Syringe units = dose volume × 100.

Example: 5 mg → 5 ÷ 33.33 = 0.15 mL → 15 units on a U-100 syringe.

Inject subcutaneously (belly, thigh, or upper arm). Rotate sites. Fresh needle each time; do not reuse.

Alternative Protocols

Topical moisturiser mix

Reconstitute as above, then blend the liquid into a plain, fragrance-free moisturiser. Apply to target areas 1–2× daily. Most human studies used cream or serum delivery. Full mixing steps: Deployment Methods · Topical.

Serum and soap (anecdotal)

GHK-Cu face serum for facial skin and GHK-Cu soap or body products for larger areas. Apply 1–2× daily where you want effects.

Microneedling (anecdotal)

Some also microneedle 1–2× per week before topical application. Pens are generally preferred over stamps or rollers. Sterility matters when skin is broken.

Injectable + topical together (anecdotal)

Common approach: injectable for systemic effects, topical for local skin. People's reports treat these as complementary.

Pre-mixed blends

GHK-Cu ships in research blends such as GLOW (GHK-Cu + BPC-157 + TB-500) and KLOW (GHK-Cu + BPC-157 + KPV + TB-500). Fixed ratios; you cannot adjust individual peptide amounts after mixing. See Blends.

Multi-vial stacks

For separate control over dose and timing, run GHK-Cu alongside other vials on a coordinated schedule. See Stacks (e.g. Full Skin, Hair Restoration).

AHK-Cu

AHK-Cu (alanine-histidine-lysine copper) is a related copper peptide often discussed for hair. Results vary; some users try both and keep whichever works better. Side-by-side clinical data vs GHK-Cu are limited.

What Is GHK-Cu

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide that binds copper(II). Loren Pickart isolated it from human plasma in 1973; GHK-Cu levels in the body decline with age, and that decline has been linked to ageing-related changes in skin repair capacity. The copper supports lysyl oxidase and other enzymes involved in collagen and elastin cross-linking.

Research focus: dermal remodelling, fibroblast activity, collagen I/III, elastin, glycosaminoglycans, and MMP/TIMP balance. Injectable human data are thinner than topical cosmetic trials, but reconstitution follows standard lyophilised peptide practice.

Supplementary Notes

Combinations (anecdotal)

• Anti-ageing / skin: Epithalon, glutathione, MOTS-c, NAD+, SS-31, Humanin, methylene blue
• Hair: minoxidil, finasteride, dutasteride, ketoconazole, RU-58841, topical androgen modulators
• Skin support: HGH (separate legal and safety profile)

Every added compound brings interaction risk. Add one thing at a time when possible.

Zinc balance (anecdotal)

Copper and zinc compete for absorption. A rough community guideline is about 1:10 copper to zinc in overall intake. Some users supplement zinc when running higher GHK-Cu doses.

Copper toxicity

Even 10 mg GHK-Cu injectable delivers roughly 1–2 mg elemental copper, far below acute toxic thresholds in published copper tox data (ATSDR Copper ToxProfile). More is not better. Stay within common dose bands.

Side effects

Injectable: injection-site redness, mild irritation.
Topical: occasional irritation or breakouts in sensitive skin.
Stop if reactions persist. Injectable route has less formal safety data than topical cosmetics.

Research

Collagen and wound repair

Rat wound-chamber models: GHK-Cu increased dry weight, DNA, protein, collagen, and GAGs in a dose-dependent way. Type I and III collagen mRNAs rose (Maquart et al., 1993). Fibroblast cultures showed direct collagen stimulation (Maquart et al., 1988).

Skin ageing and topical use

Human topical work over 8–12 weeks reports improved density, firmness, laxity, and wrinkle appearance. Thigh study: 70% collagen increase with GHK-Cu vs 50% (vitamin C) and 40% (retinoic acid) (Abdulghani et al., 1998). Facial cream data in photoaged skin over 12 weeks (Pickart & Margolina, 2018, citing Leyden et al., 2002). Nano-carrier facial trial: reduced wrinkle volume and depth (Pickart & Margolina, 2018, citing Badenhorst et al., 2016).

Gene regulation

Reviews describe GHK shifting large gene sets toward repair and away from inflammatory patterns (Pickart et al., 2015; Pickart & Margolina, 2018).

Beyond Skin

GHK-Cu’s most valuable human data comes from the topical cosmetic trials for photoaged skin. Other uses are mostly preclinical, smaller human studies, or community anecdotes. Below is what the literature actually supports, and what gets talked about online.

Hair growth

Research: A 2025 review cites a topical trial where >45 androgenetic alopecia patients had improved hair counts (MDPI review, citing earlier copper-peptide hair literature). A 2023 mouse study found topical GHK-Cu microemulsion increased scalp delivery and Wnt/β-catenin pathway activity vs controls (PMC, 2023).

Anecdotal: People have found a lot of benefits to hair density, count, and overall quality.

Wound healing

Research: This is one of the stronger non-cosmetic areas. Rat studies found huge benefits to wound related collagen, DNA, protein, etc, with 2× the collagen stimulation as normal (Maquart et al., 1993). Fibroblast collagen stimulation in culture was shown earlier (Maquart et al., 1988). GHK peptide in collagen dressings accelerated closure in rats (Arul et al., 2005). Topical GHK-Cu improved open wound healing in a dog model (Canapp et al., 2003).

Anecdotal: Injectable GHK-Cu has been found to be great for wound recovery, and scar reduction.

Pigmentation and tone

Research: 12-week topical facial trial found great improvements in skin wrinkles, colour, youthfulness, etc (Pickart & Margolina, 2018, summarising Leyden et al. and related cosmetic trial data). A comparison study vs vitamin C and retinol also tracked skin appearance and collagen markers (Abdulghani et al., 1998). Lab work on melanin pathways reports GHK-Cu can inhibit tyrosinase-related melanin synthesis in melanocyte models at tested concentrations (melanin-inhibiting natural products review, 2024).

Anecdotal: Injectable GHK-Cu has been seen to work well for melasma, post-acne scarring, or body hyperpigmentation. Topical is the route with actual human data, unless you need to penetrate deep into the skin barrier.

Joints and connective tissue

Research: In a rat ACL reconstruction model, GHK-Cu improved knee recovery vs saline at 6 weeks, but benefits faded by 12 weeks after injections stopped (Feng et al., 2015). Reviews note GHK effects on chondrocytes, fibroblasts, MMP/TIMP balance, and anti-inflammatory gene shifts, which is why it shows up in peptide discussions, however there are no large human osteoarthritis or cartilage regeneration trials.

Anecdotal: GHK-Cu has been found to be helpful for joints, tendons, and “full body collagen.”

Nerve regeneration

Research: GHK stimulates nerve outgrowth and neurotrophic signalling during skin repair (summarised in Pickart & Margolina, 2018). In rats, GHK improved nerve health (Ahmed et al., 2005). However this is nerve repair in animal models, not human trials.

Anecdotal: Injectable GHK-Cu for neuropathy symptoms or post-injury nerve recovery. No controlled human injectable data found.

Hearing

Anecdotal: Not much in the literature, but plenty of reports of better hearing and less tinnitus. Treat it as anecdote.

Cognitive and neurological effects

Research: Pickart et al., 2017 found GHK shifts hundreds of neuron-related genes (408 up, 230 down in their neuron ontology search) toward repair-oriented patterns. They discuss neurodegeneration and cognitive decline, but this is gene-expression analysis, not a clinical trial showing improved memory, focus, or dementia outcomes.

Anecdotal: General calmness, better mood, anxiety reduction, and improved focus on injectable GHK-Cu. Pickart & Margolina (2018) also summarise anti-anxiety and pain in rodents; however, that is animal data.

Other preclinical areas (brief)

Research (mostly animal or cell data, not injectable human protocols):

• Lung: COPD emphysema gene-signature reversal in lung fibroblasts and related models (Campbell et al., 2012); acute lung injury protection in mice (Park et al., 2016).
• Gut / ulcers: Pickart (2008) review cites gastric and intestinal ulcer healing in experimental models; thin human injectable data.
• Bone and liver: 2008 review summarises bone repair and hepatic protection in animal toxin models.
• Antioxidant / DNA repair: Gene-modulation and oxidative-stress work across skin and other tissues (Pickart et al., 2015; Pickart & Margolina, 2018).

Anecdotal: Systemic anti-ageing, gut healing, and organ support from daily injectable megadose cycles.

References

Skin, wound healing, and gene regulation

1. Maquart FX, Pickart L, et al. In vivo stimulation of connective tissue accumulation by GHK-Cu in rat wounds. J Clin Invest. 1993. PubMed
2. Maquart FX, Pickart L, et al. Stimulation of collagen synthesis in dermal fibroblasts by GHK-Cu. FEBS Lett. 1988. PubMed
3. Canapp SO, Farese JP, Schultz GS, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003. PubMed
4. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018. PubMed · PMC
5. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008. PubMed
6. Abdulghani AA, et al. Topical creams containing vitamin C, copper-binding peptide, and melatonin vs tretinoin. Disease Management and Clinical Outcomes. 1998. DOI
7. Pickart L, et al. GHK peptide as a natural modulator of multiple pathways in skin regeneration. Biomed Res Int. 2015. PubMed
8. Pickart L, Vasquez-Soltero JM, Margolina A. The effect of the human peptide GHK on gene expression relevant to nervous system function and cognitive decline. Brain Sci. 2017. PubMed · PMC

Beyond skin and other applications

1. Overview of short peptides for hair loss (GHK-Cu clinical and preclinical summary). Biology. 2025. DOI
2. IL microemulsion topical GHK-Cu delivery and Wnt/β-catenin in mice. Pharmaceutics. 2023. PMC
3. Arul V, et al. GHK peptide in a collagen scaffold accelerates wound healing in rats. J Biomed Mater Res B. 2005. PubMed
4. Feng Y, et al. GHK-Cu transiently improved healing in a rat ACL reconstruction model. J Orthop Res. 2015. DOI
5. Ahmed MR, et al. GHK in collagen tubes during peripheral nerve regeneration. J Peripher Nerv Syst. 2005. PubMed
6. Campbell JD, et al. GHK reverses emphysema-related gene signature in COPD. Genome Med. 2012. PubMed
7. Park JR, et al. GHK-Cu ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016. PubMed
8. Molecular understanding of melanin-inhibiting natural products (GHK-Cu tyrosinase data). RSC Adv. 2024. PMC

Storage and handling

1. NIBSC. Peptide storage guidance: lyophilised storage, moisture control, and freeze-thaw avoidance. View source
2. GenScript. Peptide handbook: lyophilised storage, reconstitution, aliquoting, and handling (PDF). View source

Injection technique and site care

1. CDC. Vaccine administration best practices: subcutaneous injection technique (angle, no aspiration). View source
2. CDC. Subcutaneous injection technique diagram and site guidance (PDF). View source
3. CDC. Pink Book, Chapter 6: Vaccine Administration (subcutaneous route and site selection). View source
4. NCBI Bookshelf. Administration of parenteral medications: asepsis, preparation, administration, and sharps disposal. View source

Safety

1. ATSDR. Toxicological Profile for Copper. U.S. Department of Health and Human Services. PDF

Leyden JJ, et al. Twelve-week topical GHK-Cu facial cream results in photoaged skin. American Academy of Dermatology 60th Annual Meeting, 2002. Conference proceedings; summarised in Pickart & Margolina, Int J Mol Sci. 2018 above.